Retrospective Study on Hepatic Enzyme Changes in Patients Treated with Risperidone and Olanzapine.
- Author:
Hyun Kook LIM
1
;
Chi Un PAE
;
Shuk Jun PARK
;
Jung Jin KIM
;
Chang Uk LEE
;
Su Jung LEE
;
Chul LEE
;
In Ho PAIK
Author Information
1. Department of Psychiatry, Kangnam St. Mary's Hospital, Korea.
- Publication Type:Original Article
- Keywords:
Hepatic enzyme elevation;
Risperidone;
Olanzapine
- MeSH:
Alanine Transaminase;
Antipsychotic Agents;
Humans;
Reference Values;
Retrospective Studies*;
Risperidone*
- From:Journal of Korean Neuropsychiatric Association
2004;43(3):283-287
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Hetapic dynfunction caused by the use of atypical antipsychotics in patients with psychiatric disorders has not been frequently reported compared to the use of typical antipsychotics. This retrospective study was aimed at assessing the differences of hepatic dysfunctions between patients treated with risperidone and olanzapine through reviewing computerized-medical records. METHODS: Charts of 667 risperidone- and olanzapin treated patients hospitalized at the department of psychiatray, Kangnam St. Mary's Hostpital, between 1998 and 2002, were reviewed. The frequencies of hepatic enzyme elevation in association with clinical variables such as time course of the use of antipsychotics were analyzed. RESULTS: Significant elevation in alanine aminotransferase (ALT) to upper reference range and 2 fold range were seen in olanzapine monotherapy patients, but not in risperidone monotherapy group. There was no difference between olanzapine and risperidone monotherapy groups in time course of hepatic dysfunction. There was no difference in hepatic enzyme elevation between resperidon and olanzapine combination therapy groups. CONCLUSION: The results suggest potential difference in degree of antipsychotic induced hepatic dysfunction between risperidone and olanzapine treatment. Well-desigend prospective study would be nessassary to extend our putative results.
